Key result
Providing BP drugs to hypertensive adults in Bangladesh could yield an ~13:1 return on investment.
Why the study?
Does providing blood-pressure lowering drugs to 60% of hypertensive adults improve return on investment in Bangladesh?
Does providing blood-pressure lowering drugs to 60% of hypertensive adults improve return on investment in Bangladesh?
Providing blood-pressure lowering drugs to 60% of hypertensive adults in Bangladesh is projected to yield substantial economic returns and prevent premature deaths.
No takes yet. Share an insight, caveat, or question.
Supports scaling hypertension programs in Bangladesh; leaves open whether modeled ROI materializes in real-world implementation.
Nugent et al. (2017) studied Hypertension. Providing blood-pressure lowering drugs to 60% of hypertensive adults was evaluated on Return on investment. Providing blood-pressure lowering drugs to 60% of hypertensive adults in Bangladesh could yield a 12.7:1 annual return on investment by 2021 and an 8.6:1 return by 2030.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: